Anaptysbio, Inc ANAB
We take great care to ensure that the data presented and summarized in this overview for ANAPTYSBIO, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ANAB
Top Purchases
Top Sells
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Insider Transactions at ANAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 29
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,000
-83.68%
|
$250,000
$25.0 P/Share
|
Nov 29
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.56%
|
$60,000
$6.93 P/Share
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-8.88%
|
$57,000
$38.67 P/Share
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+8.15%
|
$27,000
$18.5 P/Share
|
Sep 17
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,780
-53.85%
|
$143,640
$38.41 P/Share
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,220
-49.85%
|
$476,580
$39.53 P/Share
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+40.41%
|
$200,000
$20.16 P/Share
|
Sep 16
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,220
-12.6%
|
$84,360
$38.93 P/Share
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,720
-34.37%
|
$340,080
$39.53 P/Share
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+27.0%
|
$70,000
$14.02 P/Share
|
Sep 15
2024
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+28.05%
|
-
|
Sep 14
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+46.28%
|
-
|
Sep 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+25.4%
|
-
|
Sep 14
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+35.84%
|
-
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-14.69%
|
$80,000
$40.0 P/Share
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+12.81%
|
$36,000
$18.5 P/Share
|
Aug 14
2024
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
273,972
+3.4%
|
$9,862,992
$36.5 P/Share
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-11.43%
|
$52,500
$35.0 P/Share
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+10.26%
|
$27,000
$18.5 P/Share
|
Jul 15
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,000
-59.6%
|
$300,000
$30.74 P/Share
|
Last 12 Months Summary
Open market or private purchase | 274K shares |
---|---|
Exercise of conversion of derivative security | 125K shares |
Open market or private sale | 228K shares |
---|---|
Payment of exercise price or tax liability | 347K shares |